The CTC offices are currently closed for refurbishment. Access to trial TMFs and patient records will be limited during this period. We will still be able to receive post during this time, but there may be a small delay in responding to this. Our fax lines may also be subject to disruption. Where possible, please direct all correspondence via email to trial-specific email addresses. We appreciate your patience and understanding.

Due to COVID-19 and current government guidance, UCL CTC staff continue to work remotely with limited access to the office. Please continue to email the trial specific mailbox with any urgent queries. For paper CRF trials, please continue to copy and scan CRFs to the trial inboxes (remove all patient identifiers except Trial Number and Initials) until further notice.

Trial Details
Trial status:
Recruitment start date:
Chief Investigator:
Prof Stuart Taylor
Recruitment target:
EudraCT number:
Contact details:
Lay summary:
Streamlining staging of lung cancer with Whole Body MRI
Design: Multicentre comparison
Treatment: All patients will undergo a whole body MRI in addition to the standard staging protocol employed at their institution.
Key inclusion/exclusion criteria:
  • Adult patients with suspected primary NSCLC on chest CT triggering staging/biopsy, or already histologically proven primary NSCLC
  • Disease potentially radically treatable: stage IIIb or less on diagnostic CT (T1-4, N0-2, M0)
  • WHO PS 0-2

  • Evidence of severe or uncontrolled systemic disease
  • Contraindications to MRI
  • Unequivocal metastatic or N3 disease on diagnostic CT chest and abdomen (including M1a disease, malignant pleural effusion)
  • Further staging work up not indicated by MDT due to poor PS or patient choice
  • Histologies other than NSCLC.
Duration of recruitment: 4 years (closed to recruitment on 5 September 2016).
This trial evaluates whether early WB-MRI increases per patient sensitivity for metastasis in NSCLC compared to standard NICE-approved diagnostic pathways.
Trial protocols
Trial protocols must not be applied to patients treated outside trials. UCL CTC can only ensure that approved trial investigators are provided with amendments to protocols.
NameVersionCurrent versRelease dateDownload
STL_Protocol_v7_20180303_02112018_0.pdf7 Current 03/03/2018
Trial documents
NameTypeVersionCurrent versRelease dateDownload
Streamline L final paper 090519_25062019_0.pdfOthern/a Current 09/05/2019
Contact Us
Cancer Research UK & UCL Cancer Trials Centre
University College London
90 Tottenham Court Road

View map
+44 (0)20 7679 9898 (General CTC Enquiries)
020 7679 9899
University College London, Gower Street, London, WC1E 6BT +44 (0)20 7679 2000

Copyright © 2021 UCL | Disclaimer | Freedom of Information | Accessibility | Privacy | Cookies | Contact Us